Monitor NDMA levels in antacid Ranitidine: Drugs body CDSCO
NDMA (N-nitrosodimethylamine) is a chemical which has been recognised as a probable carcinogen by International Agency for Research on Cancer (IARC), reports Durgesh Nandan Jha.
CDSCO's decision came after reports of NDMA impurity in the medicine. An expert panel was appointed to deliberate on the concern in Dec last year. Sources said the the committee's recommendations were deliberated in a meeting of Drug Technical Advisory Body recently.
DTAB recommended that a larger committee be constituted to look into all aspects, including storage conditions of Ranitidine, and also suggested that the Indian Council of Medical Research undertake a study to assess the drug's safety in addition to directing manufacturers to monitor NDMA levels in the drug and, if required, take risk-based measures such as reducing the shelf life.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
2 hours ago
- Mint
India unveils first formal rules for drug approval panels in regulatory overhaul
New Delhi: India has issued its first formal playbook for how expert panels should vet new drugs, biologics and medical devices—a move aimed at fixing long-standing concerns about inconsistent and opaque approvals that have delayed critical drug launches and eroded industry trust in the regulatory system. The guidelines, issued by the Central Drugs Standard Control Organization (CDSCO), represent a major overhaul of India's drug approval process and aim to make regulatory decisions faster, more predictable and transparent, according to two government officials and documents reviewed by Mint. The guidelines standardize how Subject Expert Committees (SECs) are formed, how members are selected, and how they must evaluate applications, including the scientific benchmarks and disclosure norms they must follow. The SECs advise the Drugs Controller General of India (DCGI) on whether to clear new drugs, and their decisions have long shaped the trajectory of India's pharmaceutical industry. The CDSCO finalized the guidelines about two weeks ago and circulated them to SEC members for immediate implementation, the officials said. The overhaul follows recommendations from the World Health Organization (WHO), which last year conducted a regulatory review of CDSCO and the office of the DCGI, who heads the organization. The WHO called for stronger transparency and data integrity to align India's system with global standards. India's pharmaceutical industry ranks third globally by volume and 14th by value. It accounts for roughly 20% of the world's generic drug supply and manufactures more than 60,000 products across 60 therapeutic areas. The sector also includes over-the-counter drugs, vaccines, contract manufacturing, biologics and biosimilars. As part of its findings, the WHO urged Indian authorities to implement stronger controls to prevent, detect, and respond to substandard and falsified medical products; to launch a market surveillance program for drug quality monitoring; and to ensure that promotional and advertising claims for medicines are not misleading. These steps are now being implemented by the DCGI and other stakeholders involved in the SEC meetings, according to the officials cited earlier. The SECs play a central role in India's drug approval process, advising the DCGI on whether to approve new drugs, biologics, and medical devices. Each committee includes eight experts—one pharmacologist and seven specialists from research, medical, or regulatory institutions—and requires a four-member quorum to issue recommendations. In the absence of formal guidelines, though, these decisions were often viewed as inconsistent or opaque, delaying product approvals. 'SECs are subject expert committees involved in evaluating approvals of new drugs. Simplification and streamlining the process will help industry in getting drugs approved with predictable speed and more transparency. We appreciate the step taken by DCGI," said Dr. Viranchi Shah, national spokesperson of the Indian Drugs Manufacturers Association (IDMA). Emailed queries to the spokesperson for the health ministry went unanswered at the time of publishing. Clearer mandate, tougher benchmarks According to the guidance document, SEC members must meet strict selection criteria, including a publication record of at least 10 peer-reviewed papers and a citation ratio of 2:1. Experts are appointed for a three-year term and are expected to maintain confidentiality, impartiality, and active participation. Those who fail to attend meetings regularly may be removed. The document specifies that SECs must offer rigorous, science-based evaluations on safety, efficacy, and risk-benefit balance. It outlines the dos and don'ts of deliberations: clinical trial waiver decisions must include clear yes/no recommendations with detailed justifications, and all discussions must remain focused on scientific and regulatory issues, excluding matters such as pricing. 'For new drug and clinical trial applications, the DCGI refers them to the SEC, an expert body that discusses proposals and offers recommendations for approval or rejection. These experts, being external to CDSCO, are not always fully aware of regulatory requirements. This often led to differing, sometimes subjective opinions, a lack of uniformity in decisions, and delays on straightforward matters. Therefore, it's important for the committee to provide uniform decisions, maintain transparency, and offer proper reasoning for approvals and rejections," said one of the two government officials cited earlier, who asked not to be named. The second official added, 'There were persistent discussions during SEC meetings about the absence of a guiding document to regulate or suggest proper functioning. This new guidance note outlines the 'do's and don'ts' for experts. Previously, some companies had even alleged that SEC meetings were not being conducted properly." While officials declined to cite specific past incidents, people familiar with the matter said the lack of consistency and alignment among SEC experts, who advise on key regulatory decisions, had severely affected the functioning of the DCGI in recent years. Industry seeks consistency For years, pharmaceutical companies have raised concerns over the unpredictability of SEC verdicts, especially around clinical trial waivers, which are critical for expediting the launch of generics and biosimilars. The new rules aim to reduce such uncertainty by standardizing decision-making across similar products, unless clear scientific reasons justify a deviation. The document states: 'The SECs are indispensable in the CDSCO's evaluation process due to their specialized expertise, independent perspective and commitment to quality assurance. These committees address complex scientific and regulatory challenges, fostering informed decision-making. By operating transparently and consistently across applications, SECs bolster public trust while safeguarding public health and promoting innovation in the healthcare sector." Public health experts have welcomed the reform. 'Any committee should operate under certain guidance, and it is always beneficial for all members of such a committee to have clarity and a common vision. It's akin to laying down the rules of the game," said Dr. Chandrakant Lahariya, a physician and public health expert. He added: 'The Subject Expert Committee (SEC) is an essential requirement for guiding the drug approvals and other processes in all regulatory bodies. When a new drug is needed, the SEC provides its recommendations to the apex drug regulator. CDSCO is a regulatory organization, and they need guidance from a technical expert committee to make decisions. A regulatory body needs guidance from those who deeply understand the subject."
NDTV
19 hours ago
- NDTV
World Lung Cancer Day: Doctor Explains Why Lung Cancer In Non-Smokers Is On The Rise
World Lung Cancer Day is observed globally on August 1 to raise awareness about lung cancer, its impact, and the importance of prevention, early detection, and treatment options. The day also aims to educate individuals about the risk factors for lung cancer, including smoking, air pollution and exposure to harmful substances. It also provides a platform to support those affected by lung cancer and emphasises on the urgent need to fight against this lung cancer. According to the World Health Organisation, lung cancer is the leading cause of cancer-related deaths worldwide, with highest mortality rates among both men and women. WHO has also identified smoking as the leading cause of lung cancer, responsible for approximately 85% of all cases. Smoking not only affects the smoker but also those exposed to secondhand smoke, which can also contribute to the development of lung cancer in non-smokers. Other than secondhand smoke, many other environmental factors further exacerbate lung cancer risk in non-smokers. Understanding lung cancer in non-smokers "No cancer kills more than lung cancer. It is the most common cancer in men worldwide and is placed second when considering the number of new cancer cases in both sexes combined. It accounts for staggering 18% of all cancer deaths each year, while adding 11% to the new cancer burden during the same period. To put it straight, it's one of the cancers which have the poorest outcome," says Dr. Bhuvan Chugh, Principal Consultant - Medical Oncology, Max Hospital, Gurugram. "The primary risk factor is smoking, which accounts for up to 90% cases of all lung cancers. Smoking increases the relative risk of lung cancer by 10-30-fold, and cessation brings it down by 20-90% and is evident within 5 years of cessation," he adds. The expert further highlights that a rise in lung cancer cases has been observed in non-smokers over the past decade. "The reasons are a complex interplay between genetic and environmental factors. Environmental smoke exposure remains an important attributable risk in this population. Studies report that females have a 27 percent increased risk if partnered with an individual who smokes," Dr. Chugh states. The second most important risk factor is air pollution; the International Agency for Research on Cancer (IARC) has classified outdoor pollution and particulate matter (PM) as a Group 1 human carcinogen for lung cancer. For each 10 micrograms of a substance per cubic meter of air increase in PM2.5 and PM10 concentration over the WHO-recommended air quality guidelines, there is an 8% & 9% increase in lung cancer incidence and deaths, respectively. The difference between smokers' and non-smokers' lung cancer "There are some vital differences in the lung cancer seen in smokers vs non-smokers. The lung cancer observed in non-smokers is significantly more likely to be driven by one gene, called a driver mutation, and hence is termed as onco-gene addicted lung cancer. This onco-gene addiction provides an opportunity to target the disease by an oral tablet or targeted therapy, both in early as well as advanced stages." "This has led to improvement in tolerance to the treatment and overall survival. There are more than 10 genes identified that have been termed oncogenes for which targeted therapies are available. The majority of lung cancer patients who are diagnosed undergo genomic sequencing of their tumour for identification of these driver gene mutations before any treatment is given. This precise treatment of lung cancer, leading to improvement in survival, is a marvel of modern medicine," explains Dr. Chugh. Smoking is a modifiable risk factor for lung cancer. Quitting smoking can greatly reduce the risk of lung cancer and many other serious health conditions. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
News18
19 hours ago
- News18
Lung Cancer Myths, Risks And Signs, Doctor Shares Key Facts You Must Know
Last Updated: Lung cancer is an escalating health crisis in India, caused not just by smoking but also by air pollution, genetic predisposition, and occupational hazards. Each year on August 1, the world observes Lung Cancer Day to raise awareness about the disease and defeat the stigma associated with it. According to GLOBOCAN 2020 data by the International Agency for Research on Cancer (IARC), lung cancer remained the leading cause of cancer-related deaths in 2020, accounting for an estimated 1.8 million deaths, about 18% of all cancer fatalities, as reported by the World Health Organisation (WHO). In India too, Lung cancer is a serious public health issue, taking thousands of lives each year and affecting both smokers and non-smokers alike. According to the Indian Journal of Medical Research (2025), the number of cases in India is expected to rise from 63,807 in 2015 to 81,219 cases in 2025 It's Not Just A Smoker's Disease While smoking is the most widely known cause of lung cancer, in India, a growing number of non-smokers are being diagnosed due to environmental triggers. Dr. Mohit Sharma, Clinical Director & HOD- Medical Oncology, Marengo Asia Hospitals Faridabad, highlights that the most common misconception about lung cancer is that only smokers develop lung cancer. 'While smoking is a major risk factor for lung cancer, many times, non-smokers develop lung cancer because of environmental factors, secondhand smoke exposure, genetic mutations, radon exposure, etc," Dr Sharma says. He also notes that due to this myth, timely diagnosis in non-smokers is often put off, because early symptoms are dismissed as minor respiratory issues. 'Many people still consider lung cancer solely a smoker's disease, which is dangerous in that it fosters a false sense of security in non-smokers. Because of this misconception, many people without smoking experiences will often delay getting a checkup or diagnosis, allowing the disease to progress without medical treatment," Dr Sharma adds. As per the National Cancer Registry and GLOBOCAN 2020, India reported 85,221 new lung cancer cases and 70,264 deaths in 2020, with an age-standardised incidence rate of 7.3 per 100,000. Smoking is still the major contributor, responsible for around 60–70% of male cases and a significant portion among females. However, among Indian women, lung cancer doesn't feature among the top five cancers, indicating that other risk factors are at play. Air pollution, secondhand smoke, and workplace exposure to carcinogens are increasingly affecting non-smokers. Link Between Air Pollution and Lung Cancer in India Air pollution, especially fine particulate matter known as PM 2.5, is a key risk factor for lung cancer in India, particularly among non-smokers. The International Agency for Research on Cancer (IARC) categorised outdoor air pollution and PM2.5 as Group 1 carcinogens in 2013, directly linking them to lung cancer. PM2.5 particles are tiny (less than 2.5 microns), allowing them to reach deep into the lungs, where they cause inflammation and DNA damage that can result in cancer. Urban centres like Delhi-NCR frequently suffer from 'severe" air quality, with AQI levels above 350 due to vehicle exhaust, industrial emissions, and biomass burning. A 2023 study in Scientific Reports showed a strong link between worsening air quality and rising lung cancer deaths in India. Predictive models were able to estimate pollution levels with 81–98% accuracy. The Global Burden of Disease 2019 report found that 15% of global lung cancer deaths can be attributed to PM2.5 exposure, with India being one of the worst-affected regions. In parts of Asia, including the Western Pacific, the connection between air pollution and lung cancer is especially strong. Research from the Francis Crick Institute revealed that EGFR-mutant lung cancer is more common in areas with high PM2.5 levels, putting non-smokers with genetic vulnerabilities at even greater risk. Symptoms Lung cancer often shows no signs until it reaches an advanced stage, making early detection difficult. The common symptoms include: These symptoms usually develop slowly and are frequently confused with tuberculosis (TB) or other chronic lung diseases. As a result, diagnosis is often delayed. The Tamil Nadu Cancer Registry reports that 70% of patients in India are diagnosed at an advanced stage (35% locally advanced and 35% with metastasis), which greatly reduces the chances of survival. How Symptoms Are Often Missed Or Misunderstood Lung cancer symptoms are commonly confused with other respiratory issues. In India, air pollution worsens asthma and chronic obstructive pulmonary disease (COPD), while TB remains a prevalent diagnosis. Dr Sharma says, 'The diagnosis of lung cancer is often delayed because patients with symptoms of lung cancer, such as persistent or worsening cough, persistent fatigue, or unexplained shortness of breath, often attribute their symptoms to trivial conditions such as asthma or allergies." 'Perhaps, the most concerning phenomenon is that many patients seeking help from a medical professional only do so after the symptoms worsen – thus leading to late-stage diagnosis of lung cancer when treatment becomes more challenging," he adds. Many people seek medical help only after more serious signs, such as coughing up blood or major weight loss, appear—by which time the disease may be advanced. How Early Detection Saves Lives Dr Sharma highlights that an early-stage lung cancer is most treatable, and screening is an important factor in detecting the disease at an early stage. Detecting lung cancer early greatly improves survival rates. Globally, the five-year survival rate for lung cancer is between 10–20%, but early detection can significantly improve outcomes. In India, lung cancer is the fourth most common cancer, and with a high mortality rate (5.3 per 100,000), early diagnosis is especially crucial. 'Screening is highly recommended for people aged 50 and older with a history of heavy smoking or long-term exposure to certain exposures, such as pollutants (e.g., asbestos) or a family history of lung cancer," Dr Sharma says. Dr Sharma advises individuals at higher risk to take an annual screening for lung cancer via low-dose CT scans, which have been shown to have the potential for earlier stage detection and subsequent treatment. Low-dose computed tomography (LDCT) scans are highly effective in spotting lung cancer in people who show no symptoms but are considered high-risk, especially those aged 55–80 with a 20 pack-year smoking history or who quit recently. What Lifestyle Changes Can Lower A Person's Risk Of Lung Cancer? Dr Sharma explains that a few healthy lifestyle choices can reduce the chances of developing lung cancer. 'Stopping smoking and stopping environmental tobacco smoke like secondhand smoke are the most critical," he adds. He adds that staying active, eating plenty of fruits and vegetables, and limiting alcohol intake can help lower the risk. Avoiding exposure to air pollution, radon, and workplace carcinogens also plays a key role in reducing risk and supporting overall lung health. Quit Smoking and Avoid Tobacco: Quitting smoking is the single most effective way to reduce lung cancer risk. According to the ICMR, quitting before age 50 can reduce risk by half within 10–15 years. Avoiding smokeless tobacco (like chewing tobacco or pan) and hookah is equally important, as both beedis and cigarettes pose high risks. Limit Secondhand Smoke Exposure: Encourage those around you to quit smoking, and steer clear of smoky areas. Secondhand smoke increases a non-smoker's lung cancer risk by up to 20%. Reduce Exposure to Air Pollution: Avoid going outdoors when AQI levels are dangerously high (e.g., above 300), especially in polluted cities like Delhi. Wear N95 masks, use indoor air purifiers, and maintain good ventilation at home. Exercise Regularly: Staying active strengthens lung function and boosts overall health. Even indoor workouts during high pollution periods can lower cancer risk by improving immunity, as per Hindustan Times. Avoid Harmful Workplace Exposures: Workers in construction, mining, or industrial jobs should use proper safety gear to protect themselves from asbestos, coal dust, and other carcinogens. Get Regular Health Check-Ups: Routine screenings for high-risk individuals—such as those with a family history or living in highly polluted areas—are vital for early detection. The Times of India stresses that knowing symptoms and accessing LDCT scans can be life-saving when facilities are available. Progress In Lung Cancer Treatment top videos View all Dr Sharma notes that lung cancer treatment has advanced significantly in recent years. Newer options like immunotherapy and targeted therapies offer more personalised, effective care with fewer side effects compared to traditional chemotherapy. 'Liquid biopsies have facilitated more timely genetic mutation detection and, as a result, therapy selection. All of the above have contributed to higher survival rates and quality of life for many individuals," he adds. About the Author Surbhi Pathak Surbhi Pathak, subeditor, writes on India, world affairs, science, and education. She is currently dabbling with lifestyle content. Follow her on X: @S_Pathak_11. Get Latest Updates on Movies, Breaking News On India, World, Live Cricket Scores, And Stock Market Updates. Also Download the News18 App to stay updated! view comments Location : New Delhi, India, India First Published: August 01, 2025, 08:00 IST News explainers Lung Cancer Myths, Risks And Signs, Doctor Shares Key Facts You Must Know Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
